ArticlePloS one2024

Tolerability and efficacy of switching anti-fibrotic treatment from nintedanib to pirfenidone for idiopathic pulmonary fibrosis.

Keishi Sugino et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.